down arrow

Enveric Biosciences, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US29405E2081
USD
6.11
0.29 (4.98%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

5.886.47

52 Week

0.3096.30
Valuation
Technical
Day's Volume

CASH

52.35 k

Shareholding (Mar 2025)

FII

0.12%

Held by 5 FIIs

DII

93.83%

Held by 6 DIIs

Promoter

0.00%

How big is Enveric Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Enveric Biosciences, Inc. has a market capitalization of 3.09 million and reported net sales of 0.00 million with a net profit of -9.29 million over the last four quarters. Shareholder's funds are 1.59 million and total assets are 3.08 million as of Dec 24.

As of Jun 18, Enveric Biosciences, Inc. has a market capitalization of 3.09 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 0.00 million, while the sum of net profit for the same period is -9.29 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 1.59 million and total assets of 3.08 million.

Read More

What does Enveric Biosciences, Inc. do?

22-Jun-2025

Enveric Biosciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $2 million and a market cap of $3.09 million. Key financial metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -245.58%.

Overview:<BR>Enveric Biosciences, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 3.09 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -1.10<BR>Return on Equity: -245.58%<BR>Price to Book: 0.79<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Read More

Is Enveric Biosciences, Inc. overvalued or undervalued?

25-Jun-2025

As of March 31, 2022, Enveric Biosciences, Inc. is considered overvalued with deteriorating financial metrics, including a high ROCE of 963.23% but a negative ROE of -245.58%, and has significantly underperformed its peers and the S&P 500, with a year-to-date return of -76.75%.

As of 31 March 2022, the valuation grade for Enveric Biosciences, Inc. moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently considered overvalued given its financial metrics, including a Price to Book Value of 0.82, an EV to EBIT ratio of 0.11, and an EV to EBITDA ratio of 0.12. The company's ROCE is exceptionally high at 963.23%, but this is overshadowed by a negative ROE of -245.58%, reflecting ongoing losses.<BR><BR>In comparison to its peers, Enveric's valuation metrics are unfavorable; for instance, Paranovus Entertainment Technology Ltd. has a P/E ratio of -29.93 and an EV to EBITDA of -14.17, while Mannatech, Inc. shows a P/E of -25.45 with an EV to EBITDA of 9.59. The stark contrast in performance and valuation ratios suggests that Enveric is not only overvalued but is also struggling significantly compared to its industry peers. The company's stock has underperformed dramatically, with a year-to-date return of -76.75% compared to a 2.44% gain in the S&P 500, reinforcing the notion of its overvaluation.

Read More

Is Enveric Biosciences, Inc. technically bullish or bearish?

20-Sep-2025

As of September 4, 2025, Enveric Biosciences, Inc. is in a bearish trend, supported by negative indicators despite some mildly bullish signals, and has underperformed the S&P 500 with an 88.28% year-to-date decline.

As of 4 September 2025, the technical trend for Enveric Biosciences, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish, with key indicators supporting this view including bearish signals from the daily moving averages, weekly Bollinger Bands, KST, and Dow Theory. Although the MACD shows mildly bullish signals on both weekly and monthly time frames, the overall bearish sentiment prevails. The RSI indicates a bullish stance on the monthly but no signal on the weekly, further contributing to the mixed signals. <BR><BR>In terms of performance, Enveric has significantly underperformed compared to the S&P 500 across all multi-period returns, with a year-to-date decline of 88.28% versus the S&P 500's gain of 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 3 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.30

stock-summary
Return on Equity

-455.37%

stock-summary
Price to Book

1.34

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-51.51%
0%
-51.51%
6 Months
-59.91%
0%
-59.91%
1 Year
-89.71%
0%
-89.71%
2 Years
-97.98%
0%
-97.98%
3 Years
-98.91%
0%
-98.91%
4 Years
-99.94%
0%
-99.94%
5 Years
-99.99%
0%
-99.99%

Enveric Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Enveric Biosciences, Inc. technically bullish or bearish?

As of 4 September 2025, the technical trend for Enveric Biosciences, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish, with key indicators supporting this view including bearish signals from the daily moving averages, weekly Bollinger Bands, KST, and Dow Theory. Although the MACD shows mildly bullish signals on both weekly and monthly time frames, the overall bearish sentiment prevails. The RSI indicates a bullish stance on the monthly but no signal on the weekly, further contributing to the mixed signals. In terms of performance, Enveric has significantly underperformed compared to the S&P 500 across all multi-period returns, with a year-to-date decline of 88.28% versus the S&P 500's gain of 12.22%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
41.46%
EBIT to Interest (avg)
-9.22
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.10
Sales to Capital Employed (avg)
0
Tax Ratio
0.09%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
14.58%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.82
EV to EBIT
0.11
EV to EBITDA
0.12
EV to Capital Employed
1.08
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
963.23%
ROE (Latest)
-245.58%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (6.05%)

Foreign Institutions

Held by 5 Foreign Institutions (0.12%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -31.58% vs 70.31% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.50",
          "val2": "-1.80",
          "chgp": "-38.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.50",
          "val2": "-1.90",
          "chgp": "-31.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 44.51% vs 6.49% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.30",
          "val2": "-16.00",
          "chgp": "41.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.80",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.60",
          "val2": "-17.30",
          "chgp": "44.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-2.50
-1.80
-38.89%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.50
-1.90
-31.58%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -31.58% vs 70.31% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-9.30
-16.00
41.88%
Interest
0.00
0.00
Exceptional Items
0.00
-0.80
100.00%
Consolidate Net Profit
-9.60
-17.30
44.51%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 44.51% vs 6.49% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Enveric Biosciences, Inc. stock-summary
stock-summary
Enveric Biosciences, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."